19 Results

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Ladanyi
    Ladanyi
  4. Drilon
    Drilon
  5. Arcila
    Arcila
  6. Chaft
    Chaft
  7. Paik
    Paik
  8. Sima
    Sima
  9. Wang
    Wang
  10. Halpenny
    Halpenny

Groups

  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (19)
  4. GSK Faculty (7)
  5. Human Oncology and Pathogenesis Program (7)
  6. Body Imaging Service (4)
  7. Radiology, Department of (4)
  8. Hematologic Malignancies, Division of (3)
  9. Biostatistics Service (2)
  10. Epidemiology and Biostatistics (2)
Refine Results
  1. "anaplastic lymphoma kinase"
  2. "Thoracic Oncology"
Formats
  1. Journal Article (19)
Groups
  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (19)
  4. GSK Faculty (7)
  5. Human Oncology and Pathogenesis Program (7)
  6. Body Imaging Service (4)

More Groups

People
  1. Gregory Riely (9)
  2. Mark Kris (8)
  3. Marc Ladanyi (7)
  4. Alexander Drilon (5)
  5. Camelia Sima (3)
  6. Jamie Chaft (3)

More People

Years
  1. 2020 (3)
  2. 2018 (1)
  3. 2017 (2)
  4. 2015 (4)
  5. 2014 (4)
  6. 2013 (2)

More Years

Publications
  1. Annals of Oncology (2)
  2. Cancer (2)
  3. Journal of Thoracic Oncology (2)
  4. American Society of Clinical Oncology Educational Book (1)
  5. Clinical Cancer Research (1)
  6. Clinical Lung Cancer (1)

More Publications

Publishers
  1. Elsevier Inc. (3)
  2. Oxford University Press (3)
  3. American Association for Cancer Research (2)
  4. American Society of Clinical Oncology (2)
  5. Nature Publishing Group (2)
  6. Wiley Blackwell (2)

More Publishers

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients
    Journal Article

    Ross, D. S.; Liu, B.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Complete pathological response to crizotinib in a patient with ALK-rearranged lung adenocarcinoma
    Journal Article

    Mattar, M. S.; Chang, J.; Benayed, R.; Halpenny, D.; Powers, A.; Kleiner, D. E.; Drilon, A.; Kris, M. G.
    Clinical Lung Cancer (2020)

    Fulltext@MSK | Save
  • Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors
    Journal Article

    Lin, J. J.; Schoenfeld, A. J.; Zhu, V. W.; Yeap, B. Y.; Chin, E.; Rooney, M.; Plodkowski, A. J.; Digumarthy, S. R.; Dagogo-Jack, I.; Gainor, J. F.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • Brigatinib in patients With alectinib-refractory ALK-positive NSCLC
    Journal Article

    Lin, J. J.; Zhu, V. W.; Schoenfeld, A. J.; Yeap, B. Y.; Saxena, A.; Ferris, L. A.; Dagogo-Jack, I.; Farago, A. F.; Taber, A.; Traynor, A.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers
    Journal Article

    Santini, F. C.; Salhab, R. M.; Sharma, S.; Drilon, A.
    Translational Cancer Research (2017)

    Fulltext@MSK | Save
  • Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer
    Journal Article

    Dagogo-Jack, I.; Shaw, A. T.; Riely, G. J.
    Clinical Pharmacology & Therapeutics (2017)

    Fulltext@MSK | Save
  • Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
    Journal Article

    Davare, M. A.; Vellore, N. A.; Wagner, J. P.; Eide, C. A.; Goodman, J. R.; Drilon, A.; Deininger, M. W.; O'Hare, T.; Druker, B. J.
    Proceedings of the National Academy of Sciences of the United States of America (2015)

    Fulltext@MSK | Save
  • Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches
    Journal Article

    Drilon, A.; Wang, L.; Arcila, M. E.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; Kris, M. G.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases
    Journal Article

    Costa, D. B.; Shaw, A. T.; Ou, S. H. I.; Solomon, B. J.; Riely, G. J.; Ahn, M. J.; Zhou, C. C.; Shreeve, M.; Selaru, P.; Polli, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
    Journal Article

    Villaruz, L. C.; Socinski, M. A.; Abberbock, S.; Berry, L. D.; Johnson, B. E.; Kwiatkowski, D. J.; John Iafrate, A.; Varella-Garcia, M.; Franklin, W. A.; Camidge, D. R.; more...
    Cancer (2015)

    Fulltext@MSK | Save